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The manuscript reports synthesis and antimicrobial activity of several novel heterocyclic compounds in which  
1,4-disubstituted 1,2,3-triazole synthesized via click chemistry approach and 4-aryl (5a-h) and 4-piperazinyl amide (7a-e) or 
4-aryl amide (8a-e) substituted thiazole rings, are bridged through hydrazine linkage. Structures of all the synthesized 
compounds have been elucidated using 1H and 13C NMR and mass spectral analysis. In vitro antimicrobial screening of the 
target compounds has been carried out against six bacterial species viz. E. coli, P. aeruginosa, B. subtilis, S. pyogenes,  
K. pneumoniae and S. aureus and four fungal species viz. C. albicans, T. viride, A. flavus and A. brasiliensis. The activity 
study revealed that many of the compounds possess moderate to good activity against the tested microorganisms. The active 
compounds have been further studied to determine the minimum inhibitory concentration (MIC). 
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The resistance observed for the existing drugs by 
newly emerging pathogenic bacteria has become one 
of the major concern for the medicinal scientists. Due 
to the resistive developments in the microorganisms, 
the existing drugs lack in the efficient treatment of 
microbial infections. Also, due to their slower effects, 
toxicity, and undesired side effects; these drugs 
become less efficient against the microorganisms. As 
a consequence, in past few decades the multi-drug 
resistant bacteria have drastically affected the human 
health. These facts have constantly underlined the 
need for more effective compounds. 
The exhaustive research in the field of medicinal 
chemistry has proved that, a heterocyclic ring is the 
dominant part of biologically active compounds and 
most of the times is responsible for the activity of that 
compound.  
Due to the wide range of activities, heterocyclic 
compounds have now become the most significant 
and interesting area of research. Among these 
bioactive heterocycles, 1,2,3-triazoles are found to have 
various biological activities such as antimicrobial1-4, 
anti-phytopathogenic5, antimycobacterial6, anti-
proliferative7, anticancer8-10, anti-Alzheimer’s11, anti-
diabetic12, antitubercular13, 14, antiepileptic15, antiviral16. 
Several drugs like carboxyamidotriazole, 
cefatrizine, tazobactam bear 1,2,3-triazole in their 
structure. Moreover, Rufinamide, the amide of  
1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic 
acid is an antiepileptic drug, which is used in the 
treatment of partial seizures and drop attacks 
associated with the Lennox-Gastaut syndrome17. 
Similarly, thiazole ring has also marked its place in 
the field of medicinal chemistry. Alagebrium, 
amthamine, ceftibuten, clomethiazole, fentiazac are 
some drugs containing thiazole ring in their structure. 
Various activities possessed by different thiazole 
derivatives are reported in literature. Few of them are 
anti-inflammatory18, anticancer19,20, antiviral21, 
antimicrobial22-26, activities. Heterocyclic compounds 
containing thiazole along with hydrazine chain are 
also found to cover a broad spectrum of biological 
activities such as anti-parasitic27, monoamine oxidase 
inhibitor28, antimicrobial29-31. 
In view of these findings and in pursuing our 
continuous interest in designing and synthesizing 
different heterocyclic compounds as possible bioactive 
precursors32-40, we herein report synthesis and 
antimicrobial evaluation of thiazolylhydrazine derivatives 
of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carbaldehyde. 
 
Result and Discussion 
As shown in Scheme I, the synthesis of  
target compounds 5a-h was initiated using  




2,6-difluorobenzyl azide 1 which was prepared by 
literature reported procedure37. Compound 1 was 
cyclized with propargyl alcohol using click chemistry 
approach to obtain the corresponding (1-(2,6-
difluorobenzyl)-1H-1,2,3-triazol-4-yl)methanol (2). 
Structure of compound 2 was established by 1H and 
13C NMR analysis. In 1H NMR, two peaks were 
observed at δ 4.73 (-CH2OH) and 5.60 (Ar-CH2). In 
addition, a singlet at δ 7.57 (triazole-H) confirmed 
formation of expected 1,2,3-triazole ring. The 
13C NMR displayed two peaks at δ 41.4 and 56.3 for 
the two methylene carbons. Further, oxidation of the 
alcohol 2 to corresponding aldehyde 3 was achieved 
by using Jone’s reagent at 0°C. A singlet  
for aldehydic proton was observed at δ 10.12 in  
the1H NMR spectrum of compound 3. Refluxing 
aldehyde 3 with thiosemicarbazide gave the  
1-((1-(2,6-difluorobenzyl)-1H-1,2,3-triazol-4-yl) 
methylene)thiosemicarbazide 4. Formation of 
compound 4 was ascertained by 1H and 13C NMR 
analysis. In the 1H NMR, the disappearance of 
aldehydic proton and appearance of a new singlet at δ 
8.43 for imine proton confirmed formation of the 
compound 4. The thiosemicarbazide derivative 4 was 
reacted with different substituted phenacyl bromides 
in ethanol to afford the corresponding target 
compounds 5a-h. Structures of all the synthesized 
target compounds 5a-h were established by 1H  
and 13C NMR and LC-MS spectral analysis.  
For instance, the 1H NMR spectrum of 5d displayed  
a peak at δ 7.31 (thiazole ring proton) which 
confirmed the formation of thiazole ring. Further,  
the LC-MS spectrum showed [M+H]+peak at 
415.0944. (molecular formula C19H13F3N6S and  
exact mass 414.0874).  
Similarly, synthesis of the target compounds 7a-e 
and 8a-e was achieved as depicted in Scheme II. 
Compound 4 was treated with bromopyruvic acid in 
ethanol to afford the corresponding thiazole-4-
carboxylic acid derivative 6. Formation of thiazole 
ring was confirmed by 1H NMR spectral analysis in 
which the thiazole proton appeared at δ 7.69.Coupling  
of acid 6 with different substituted piperazines and 
anilines provided the target compounds 7a-e and  
8a-e, respectively. All the target compounds were 
characterized by 1H NMR and LC-MS spectral analysis. 
1H NMR spectrum of compound 7d displayed three 
peaks as broad singlet for piperazine protons at δ 2.92, 
3.51 and 3.98, respectively while methyl group protons 
appeared as singlet at δ 2.15. LC-MS spectrum of 
compound 7d having molecular formulaC25H24F2N8OS 
and exact mass 522.1762 showed [M+H]+peak at 
523.1828. 1H NMR spectrum of compound 8c revealed 
aromatic protons of 4-fluorophenyl rings as two 
multiplets at δ 7.07-7.18 and 7.87-7.91, respectively and 
two -NH protons at δ 10.25 and 12.55. LC-MS spectrum 
of compound 8c showed [M+H]+peak at 458.0999 
against exact mass 457.0933. All the newly synthesized 
derivatives displayed suitable spectral data in 
accordance with the expected structures. 
 
 
Scheme I — Synthetic scheme for the compounds 5a-h 
 





Antimicrobial screening of the target compounds 5a-
h, 7a-e and 8a-e was performed using agar disc 
diffusion assay method against six bacterial strains 
namely E. coli, P. aeruginosa, B. subtilis, S. pyogenes, 
K. pneumonia, S. aureus and four fungal strains,  
C. albicans, T. viride, A. flavus and A. brasiliensis. The 
zone of inhibition (in mm of diameter) and minimum 
inhibitory concentration values (MICs) in µg/mL were 
determined. Discs measuring 6mm diameter were 
prepared from sterile Whatmann paper. Test solution 
concentration and positive control concentration was 
kept 100 µg/mL. After loading the sample discs on the 
agar plate, the plates were inoculated at 37°C for 24 h 
and the zone of inhibition was measured thereafter using 
digital vernier caliper. 
From the results obtained (Table I and Table II), it 
was evident that, many of the tested compounds 
exhibited moderate to good inhibition of the  
tested microorganisms. Aryl thiazole derivative 
5cwith 4-chlorophenyl ring on thiazole, showed  
good antibacterial activity as compared to its  
4-bromophenyl analogue 5b and 4-fluorophenyl 
analogue 5d. Compound 5h bearing (3-fluoro-4-
methoxy)phenyl substitution was inactive against all 
tested bacterial species but showed antifungal activity 
against three out of four tested species. 
Compounds 7a-e, 8d and 8e showed enhanced 
activity against bacteria E. coli. Piperazinyl amides 
7a-ewere slightly more effective towards tested 
bacteria as compared to the N-aryl amide derivatives 
8a-e. In case of fungal strains, compound 8a and 8c 
exhibited noticeable activity against all tested  
fungal species. Most of the tested compounds 
exhibited promising activity against A. brasiliensis. 
N-aryl amides 8a-ewere found more active against 




The reagents and solvents used were of AR grade,  
and used without any further purification. Thin Layer 
Chromatography was used to monitor reactions.  
1H and 13C NMR spectra were recorded on  
Varian Mercury 300, Brucker Advance II 400 and  
500 spectrometers. CDCl3 or DMSO-d6 were used as 
solvents. Chemical shifts are expressed in δ (ppm) 
unit downfield to internal standard TMS. The 
assignment of spectra is expressed using standard 
notations for chemical shifts (δ), splitting patterns  
(s, d, t, q, m), coupling constants (J in Hz). 
High resolution mass spectra were recorded  




Scheme II — Synthetic scheme for the compounds 7a-e and 8a-e 
 





Table I — Antimicrobial activity of the compounds 4, 5a-h, 6, 7a-e and 8a-e; diameter of inhibition zone in mm 
Compd Microorganisms* 
A B C D E F G H I J 
4 17.01 20.16 18.00 -† 19.94 18.97 20.04 -† -† -† 
5a 19.06 20.14 -† -† 19.97 -† 18.01 17.65 18.54 18.00 
5b 19.00 16.54 16.62 15.58 16.37 17.68 18.00 -† -† 18.87 
5c 20.03 -† 18.97 17.52 -† 19.36 17.33 18.61 -† 16.44 
5d -† 19.00 -† -† -† -† -† 17.66 16.98 19.67 
5e 18.87 19.23 -† -† 18.88 -† -† -† -† -† 
5f -† -† 18.97 17.25 -† 18.68 18.97 -† -† -† 
5g 17.32 17.27 -† -† 19.00 -† 18.00 -† -† -† 
5h -† -† -† -† -† -† -† 18.16 17.98 20.07 
6 17.62 -† 19.11 20.00 18.67 19.03 17.24 -† -† -† 
7a 18.61 18.94 -† -† 19.98 -† 19.48 -† 20.08 19.88 
7b 18.66 20.04 19.15 -† -† 19.32 20.06 -† -† 19.72 
7c 19.32 19.23 19.66 -† -† 20.11 19.76 -† -† 19.53 
7d 18.94 -† -† 19.53 -† -† -† -† 20.02 19.13 
7e 18.92 -† 18.81 19.90 19.07 20.11 18.68 -† -† -† 
8a -† -† 19.07 -† -† 18.24 19.13 18.33 19.24 19.41 
8b -† -† -† 19.23 -† -† -† -† 20.13 17.96 
8c -† -† 19.28 -† -† 19.37 20.19 19.12 20.14 19.53 
8d 20.00 19.47 19.13 -† -† 19.61 20.06 -† -† 20.15 
8e 19.32 18.64 -† -† 18.88 -† -† -† -† -† 
Chloram-phenicol 21.84 22.93 21.90 22.88 22.67 22.97 NA‡ NA‡ NA‡ NA‡ 
Nystatin NA‡ NA‡ NA‡ NA‡ NA‡ NA‡ 22.27 22.03 23.07 22.83 
*(A) E. coli; (B) P. aeruginosa; (C) B. subtilis; (D) S. pyogenes; (E) K. pneumonia; (F) S. aureus; (G) C. albicans; (H)T. viride;
(I) A. flavus; (J) A. brasilliansis; † (-) Inactive; ‡ (NA) Not Applicable 
 
Table II — Antimicrobial activity of the compounds 4, 5a-h, 6, 7a-e and 8a-e; minimum inhibitory concentrations (MIC) in µg/mL 
Compd Microorganisms* 
A B C D E F G H I J 
4 90 50 60 -† 60 60 50 -† -† -† 
5a 70 50 -† -† 60 -† 60 80 70 60 
5b 70 80 80 90 80 80 60 -† -† 60 
5c 60 -† 60 80 -† 70 80 70 -† 80 
5d -† 60 -† -† -† -† -† 80 80 50 
5e 80 60 -† -† 70 -† -† -† -† -† 
5f -† -† 60 80 -† 80 50 -† -† -† 
5g 90 70 -† -† 70 -† 60 -† -† -† 
5h -† -† -† -† -† -† -† 70 80 50 
6 80 -† 60 60 80 70 90 -† -† -† 
7a 70 60 -† -† 70 -† 70 -† 60 70 
7b 70 50 60 -† -† 70 60 -† -† 70 
7c 60 60 60 -† -† 60 70 -† -† 70 
7d 70 -† -† 70 -† -† -† -† 60 70 
7e 70 -† 70 60 70 60 80 -† -† -† 
8a -† -† 60 -† -† 90 70 90 70 70 
8b -† -† -† 70 -† -† -† -† 60 90 
8c -† -† 60 -† -† 70 60 80 60 70 
8d 60 60 60 -† -† 70 60 -† -† 60 
8e 70 70 -† -† 80 -† -† -† -† -† 
Chloram-phenicol 50 40 40 50 50 50 NA‡ NA‡ NA‡ NA‡ 
Nystatin NA‡ NA‡ NA‡ NA‡ NA‡ NA‡ 40 60 50 40 
*(A) E. coli; (B) P. aeruginosa; (C) B. subtilis; (D) S. pyogenes; (E) K. pneumonia; (F) S. aureus; (G) C. albicans; (H)T. viride;
(I) A. flavus; (J) A. brasilliansis; † (-) Inactive; (NA) Not Applicable 






To a solution of sodium ascorbate (0.2 mol) in 
aqueous copper sulphate pentahydrate (0.2 mol), 
propargyl alcohol (1.0 mol) in tert-butanol was added 
slowly and the mixture was stirred for 15 min. Azide 2 
(1.0 mol) was added thereafter, portion wise with 
stirring. After the complete addition, the reaction 
mixture was stirred further at RT. After completion of 
the reaction, the excess solvent was removed and the 
solid obtained was filtered, washed with water. The 
product was purified by column chromatography using 
hexane-ethyl acetate as eluent. Yield 88%. m.p.87-90°C. 
1H NMR (400 MHz, CDCl3): δ 4.73 (s, 2H, CH2-OH), 
5.60 (s, 2H, -CH2), 6.93-6.97 (m, 2H, Ar-H), 7.33-7.37 
(m, 1H, Ar-H), 7.57 (s, 1H, triazole-H); 13C NMR (100 
MHz, CDCl3): δ 41.4, 56.3, 110.7, 111.8, 112.0, 121.8, 




To a solution of compound 2(1.0 mol) in dry 
acetone at 0°C, freshly prepared Jone’s reagent was 
added drop wise under cold conditions. After the 
addition was complete, the mixture was stirred further 
and reaction was monitored on TLC. After 
completion of the reaction, isopropyl alcohol was 
added slowly to consume the excess Jone’s reagent. 
The mixture was then filtered through celite bed. The 
excess solvent was removed and the solid obtained 
was washed with water. Yield 84%. m.p.104-107°C. 
1H NMR (400 MHz, CDCl3): δ 5.71 (s, 2H, -CH2), 
6.98-7.04 (m, 2H, Ar-H), 7.38-7.46 (m, 1H, Ar-H), 
8.14 (s, 1H, triazole-H), 10.12 (s, 1H, -CHO); 
13C NMR (100 MHz, CDCl3): δ 41.8, 109.7, 111.9, 




Mixture of aldehyde derivative 3 (1.0 mol) and 
thiosemicarbazide (1.0 mol) in ethanol was refluxed 
for 3 h. After the reaction was complete, the excess 
solvent was removed and the solid obtained was 
filtered, washed with cold ethanol. Yield 92%. 
m.p.154-156°C. 1H NMR (400 MHz, DMSO-d6): δ 
5.67 (s, 2H, -CH2), 7.04-7.08 (m, 2H, Ar-H), 7.42-
7.49 (m, 1H, Ar-H), 7.77 (s, 1H, -NH), 8.02 (s, 1H, -
SH), 8.15 (s, 1H, triazole-H), 8.43 (s, 1H, -CH=N), 
11.5 (s, 1H, -NH); 13C NMR (100 MHz, DMSO-d6): δ 
41.0, 110.4, 111.5, 122.5, 126.1, 131.4, 134.1, 141.5, 
143.9, 159.5, 162.0, 178.0, 178.9. 
General procedure for the synthesis of 1-((1-(2,6-
difluorobenzyl)-1H-1,2,3-triazol-4-yl)methylene)-2-
(4-arylthiazol-2-yl)hydrazine, 5a-h 
Equimolar quantities of thiosemicarbazide 
derivative 4 and corresponding substituted phenacyl 
bromide were refluxed in ethanol for 2 h. The reaction 
mixture was then cooled to RT. The solid separated 
was filtered, washed with cold ethanol. All the 
synthesized compounds were purified by column 
chromatography using hexane-ethyl acetate as eluent. 
1-((1-(2,6-Difluorobenzyl)-1H-1,2,3-triazol-4-yl) 
methylene)-2-(4-phenylthiazol-2-yl)hydrazine, 5a: 
Yield 82%. m.p.210-212°C. 1H NMR (500 MHz, 
DMSO-d6): δ 5.71 (s, 2H, -CH2), 6.97-7.06 (m, 3H, 
Ar-H, thiazole-H), 7.22-7.35 (m, 3H, Ar-H),  
7.48-7.61 (m, 3H, Ar-H), 8.14 (s, 1H, triazole-H), 
8.36 (s, 1H, -CH=N), 12.36 (s, 1H, -NH). 
1-((1-(2,6-Difluorobenzyl)-1H-1,2,3-triazol-4-yl) 
methylene)-2-(4-(4-bromophenyl)thiazol-2-yl) 
hydrazine, 5b: Yield 86%. m.p.231-233°C. 1H NMR 
(400 MHz, DMSO-d6): δ 5.69 (s, 2H, -CH2),  
7.10-7.14 (m, 3H, Ar-H, thiazole-H), 7.46-7.53  
(m, 1H, Ar-H), 7.73 (d, 2H, J = 7.8 Hz, Ar-H), 7.93 
(d, 2H, J = 7.8 Hz, Ar-H), 8.17 (s, 1H, triazole-H), 
8.82 (s, 1H, -CH=N); 13C NMR (100 MHz, DMSO-
d6): δ 41.3, 110.5, 111.6, 111.7, 111.8, 122.3, 126.8, 




hydrazine, 5c: Yield 88%. m.p.163-165°C. 1H NMR 
(400 MHz, DMSO-d6): δ 5.71 (s, 2H, -CH2),  
7.11-7.15 (m, 2H, Ar-H), 7.26 (s, 1H, thiazole-H), 
7.40 (d, 2H, J = 8.1 Hz, Ar-H), 7.47-7.52 (m, 1H,  
Ar-H), 7.84 (d, 2H, J = 8.1 Hz, Ar-H), 8.10 (s, 1H, 
triazole-H), 8.38 (s, 1H, -CH=N), 12.12 (s, 1H, -NH). 
1-((1-(2,6-Difluorobenzyl)-1H-1,2,3-triazol-4-yl) 
methylene)-2-(4-(4-fluorohenyl)thiazol-2-yl) 
hydrazine, 5d: Yield 84%. m.p.223-225°C. 1H NMR 
(500 MHz, DMSO-d6): δ 5.71 (s, 2H, -CH2),  
7.07-7.25 (m, 4H, Ar-H), 7.31 (s, 1H, thiazole-H), 
7.48-7.57 (m, 1H, Ar-H), 7.81-7.90 (m, 2H, Ar-H), 
8.12 (s, 1H, triazole-H), 8.50 (s, 1H, -CH=N),  
12.18 (s, 1H, -NH); 13C NMR (125 MHz, DMSO-d6): 
δ 41.1, 111.1, 111.9, 115.4, 122.9, 126.8,  
127.6, 129.9, 131.0, 131.8, 133.7, 143.1, 149.0,  
159.8, 160.6, 161.8, 162.9, 167.9;LC-MS [M+H]+: 
415.0944. 






hydrazine, 5e: Yield 81%. m.p.227-230°C. 1H NMR 
(500 MHz, DMSO-d6): δ 3.80 (s, 3H, -OCH3), 5.68  
(s, 2H, -CH2), 6.97-7.02 (m, 4H, Ar-H), 7.14 (s, 1H, 
thiazole-H), 7.54-7.56 (m, 1H, Ar-H), 7.70-7.73  
(m, 2H, Ar-H), 7.95 (s, 1H, triazole-H), 8.12 (s, 1H, -
CH=N), 11.20 (s, 1H, -NH); 13C NMR (125 MHz, 
DMSO-d6): δ 41.5, 55.2, 101.8, 113.4, 113.5, 113.9, 




Yield 89%. m.p.216-218°C. 1H NMR (400 MHz, 
DMSO-d6): δ 2.71 (s, 3H, -CH3), 5.72 (s, 2H, -CH2), 
7.14-7.21 (m, 3H, Ar-H, thiazole-H), 7.49-7.53  
(m, 3H, Ar-H), 7.78-7.82 (m, 2H, Ar-H), 8.13  
(s, 1H, triazole-H), 8.36 (s, 1H, -CH=N), 12.09  
(s, 1H, -NH). 
1-((1-(2,6-Difluorobenzyl)-1H-1,2,3-triazol-4-yl) 
methylene)-2-(4-(2,4-dichloro--phenyl)thiazol-2-yl) 
hydrazine, 5g: Yield 83%. m.p.191-194°C. 1H NMR 
(400 MHz, DMSO-d6): δ 5.74 (s, 2H, -CH2),  
7.09-7.17 (m, 3H, Ar-H, thiazole-H), 7.39-7.53  
(m, 3H, Ar-H), 7.95 (d, 1H, J = 8.5 Hz, Ar-H),  
8.60 (s, 1H, triazole-H), 8.71 (s, 1H, -CH=N), 12.44 
(s, 1H, -NH). 
1-((1-(2,6-Difluorobenzyl)-1H-1,2,3-triazol-4-yl) 
methylene)-2-(4-(3-fluoro-4-methoxyphenyl)thiazol- 
2-yl)hydrazine, 5h: Yield 79%. m.p.219-220°C. 
1H NMR (400 MHz, DMSO-d6): δ 3.91 (s, 3H, -
OCH3), 5.67 (s, 2H, -CH2), 6.97-7.03 (m, 4H, Ar-H, 
thiazole-H), 7.47-7.51 (m, 3H, Ar-H), 7.95 (s, 1H, 
triazole-H), 7.97 (s, 1H, -CH=N). 
 
Synthesis of 2-(((1-(2,6-difluorobenzyl)-1H-1,2, 
3-triazol-4-yl)methylene)hydrazin-1-yl)thiazole-
4-carboxylic acid, 6 
Bromopyruvic acid (1.0 mol) was added to a 
solution of compound 4 (1.0 mol) in ethanol and the 
resulting mixture was refluxed for 3 h. After the 
reaction was complete, the excess solvent was 
removed. The solid obtained was filtered and washed 
with cold ethanol. Yield 82%. m.p.214-216°C. 
1H NMR (500 MHz, DMSO-d6): δ 5.71 (s, 2H, -CH2), 
7.17-7.20 (m, 2H, Ar-H), 7.49-7.54 (m, 1H, Ar-H), 
7.69 (s, 1H, thiazole-H), 8.05 (s, 1H, triazole-H), 8.49 
(s, 1H, -CH=N). 
 
General procedure for the synthesis of (2-(((1-(2,6-
difluorobenzyl)-1H-1,2,3-triazol-4-yl)methylene) 
hydrazin-1-yl)thiazol-4-yl)(4-substitutedpiperazin-
1-yl)methanone 7a-e or N-(substitutedphenyl)-1- 
(2-(((1-(2,6-difluorobenzyl)-1H-1,2,3-triazol-4-yl) 
methylene)hydrazin-1-yl)thiazole-4-carboxamide, 8a-e 
To a cooled solution of 2-(((1-(2,6-difluorobenzyl)-
1H-1,2,3-triazol-4-yl)methylene)hydrazin-1-yl) 
thiazole-4-carboxylic acid 6 (1.0 mol) in DMF, HOBt 
(1.0 mol) was added followed by corresponding 
piperazine (1.0 mol) or substituted aniline (1.0 mol). 
TEA (2.0 mol) and EDC.HCl (1.0 mol) were  
added thereafter and the reaction mixture was left 
overnight for stirring. The mixture was then  
poured on to crushed ice; the product was filtered  
and washed with water. The final products were 
purified by column chromatography using hexane-
ethyl acetate as eluent. 
(2-(((1-(2,6-Difluorobenzyl)-1H-1,2,3-triazol-4-
yl)methylene)hydrazin-1-yl)thiazol-4-yl)(4-boc-
piperazin-1-yl)methanone, 7a: Yield 89%. m.p.175-
177°C. 1H NMR (500 MHz, DMSO-d6): δ 1.33  
(s, 9H, -C(CH3)3), 2.91 (bs, 4H, piperazine-H), 3.55 
(bs, 2H, piperazine-H), 4.01 (bs, 2H, piperazine-H), 
5.89 (s, 2H, -CH2), 7.10-7.14 (m, 2H, Ar-H), 7.35  
(s, 1H, thiazole-H), 7.45-7.47 (m, 1H, Ar-H), 8.14 
 (s, 1H, triazole-H), 8.55 (s, 1H, -CH=N), 12.08  
(bs, 1H, -NH); LC-MS [M+H]+: 533.1886. 
(2-(((1-(2,6-Difluorobenzyl)-1H-1,2,3-triazol-4-yl) 
methylene)hydrazin-1-yl)thiazol-4-yl)(4-(2-methoxy-
phenyl)piperazin-1-yl)methanone, 7b: Yield 87%. 
m.p.180-182°C. 1H NMR (500 MHz, DMSO-d6): δ 
2.94 (bs, 4H, piperazine-H), 3.60 (bs, 2H, piperazine-
H), 4.03 (bs, 2H, piperazine-H), 5.81 (s, 2H, -CH2), 
7.09-7.12 (m, 2H, Ar-H), 7.32 (s, 1H, thiazole-H), 
7.49-7.51 (m, 1H, Ar-H), 8.17 (s, 1H, triazole-H), 




methyl)phenyl)piperazin-1-yl)methanone, 7c: Yield 
84%. m.p.180-182°C. 1H NMR (500 MHz, DMSO-
d6): δ 2.89 (bs, 4H, piperazine-H), 3.58 (bs, 2H, 
piperazine-H), 4.02 (bs, 2H, piperazine-H), 5.77  
(s, 2H, -CH2), 7.06-7.10 (m, 2H, Ar-H), 7.38 (s, 1H, 
thiazole-H), 7.41-7.46 (m, 1H, Ar-H), 8.12 (s, 1H, 
triazole-H), 8.51 (s, 1H, -CH=N), 12.13 (bs, 1H, -
NH); LC-MS [M+H]+: 577.1555. 






tolylpiperazin-1-yl)methanone, 7d: Yield 91%. 
m.p.150-151°C. 1H NMR (500 MHz, DMSO-d6): δ 
2.15 (s, 3H, -CH3),2.92 (bs, 4H, piperazine-H), 3.51 
(bs, 2H, piperazine-H), 3.98 (bs, 2H, piperazine-H), 
5.71 (s, 2H, -CH2), 6.84-6.86 (d, 2H, J = 8.1 Hz, Ar-
H), 7.02-7.06 (d, 2H, J = 8.1 Hz, Ar-H), 7.10-7.15  
(m, 2H, Ar-H), 7.35 (s, 1H, thiazole-H), 7.45-7.49  
(m, 1H, Ar-H), 8.18 (s, 1H, triazole-H), 8.59 (s, 1H, -




benzyl)piperazin-1-yl)methanone, 7e: Yield 82%. 
m.p.130-140°C. 1H NMR (500 MHz, DMSO-d6): δ 
2.92 (bs, 4H, piperazine-H), 3.51 (bs, 2H, piperazine-
H), 3.98 (bs, 2H, piperazine-H), 4.30 (s, 2H, Ar-CH2), 
5.75 (s, 2H, -CH2), 7.09-7.12 (m, 2H, Ar-H), 7.27-
7.30 (m, 2H, Ar-H), 7.33 (s, 1H, thiazole-H), 7.46-
7.52 (m, 3H, Ar-H), 8.13 (s, 1H, triazole-H), 8.48  
(s, 1H, -CH=N), 12.15 (bs, 1H, -NH). 
N-Phenyl-1-(2-(((1-(2,6-difluorobenzyl)-1H-1,2, 
3-triazol-4-yl)methylene)hydrazin-1-yl)thiazole-4-
carboxamide, 8a: Yield 79%; m,p: 143-145°C. 
1H NMR (500 MHz, DMSO-d6): δ 2.95 (bs, 4H, 
piperazine-H), 3.56 (bs, 2H, piperazine-H), 4.01  
(bs, 2H, piperazine-H), 5.73 (s, 2H, -CH2), 7.01-7.08 
(m, 3H, Ar-H), 7.24-7.27 (m, 2H, Ar-H), 7.38 (s, 1H, 
thiazole-H), 7.49-7.54 (m, 1H, Ar-H), 7.79-7.84  
(m, 2H, Ar-H), 8.09 (s, 1H, triazole-H), 8.51 (s, 1H, -
CH=N), 10.27 (s, 1H, -NH), 12.09 (s, 1H, -NH); LC-
MS [M+H]+: 440.1098. 
N-(4-Chlorophenyl)-1-(2-(((1-(2,6-difluorobenzyl)- 
1H-1,2,3-triazol-4-yl)methylene) hydrazin-1-yl) 
thiazole-4-carboxamide, 8b: Yield 82%. m.p. 
159-161°C. 1H NMR (500 MHz, DMSO-d6): δ 5.85 
(s, 2H, -CH2), 7.07-7.11 (m, 2H, Ar-H), 7.36-7.39  
(m, 3H, Ar-H, thiazole-H), 7.43-7.48 (m, 1H, Ar-H), 
7.81 (d, 2H, J = 8.6 Hz, Ar-H), 8.05 (s, 1H, triazole-
H), 8.59 (s, 1H, -CH=N), 10.25 (s, 1H, -NH), 12.51 
(s, 1H, -NH). 
N-(4-Fluorophenyl)-1-(2-(((1-(2,6-difluorobenzyl)-
1H-1,2,3-triazol-4-yl)methylene) hydrazin-1-yl) 
thiazole-4-carboxamide, 8c: Yield 77%. m.p.148-
150°C. 1H NMR (500 MHz, DMSO-d6): δ 5.82  
(s, 2H, -CH2), 7.07-7.18 (m, 4H, Ar-H), 7.39 (s, 1H, 
tiazole-H), 7.51-7.55 (m, 1H, Ar-H), 7.87-7.91  
(m, 2H, Ar-H), 8.05 (s, 1H, triazole-H), 8.62 (s, 1H, -
CH=N), 10.25 (s, 1H, -NH), 12.55 (s, 1H, -NH);  
LC-MS [M+H]+: 458.0999. 
N-(4-Methoxyphenyl)-1-(2-(((1-(2,6-difluorobenzyl)-
1H-1,2,3-triazol-4-yl)methylene)hydrazin-1-yl) 
thiazole-4-carboxamide, 8d: Yield 85%. m.p.105-
107°C. 1H NMR (500 MHz, DMSO-d6): δ 3.76  
(s, 3H, -OCH3), 5.82 (s, 2H, -CH2),6.86 (d, 2H, J = 
9.0 Hz, Ar-H), 7.10-7.14 (m, 2H, Ar-H), 7.34 (s, 1H, 
thiazole-H), 7.43-7.48 (m, 1H, Ar-H), 7.75-7.79  
(d, 2H, J = 9.0 Hz, Ar-H), 8.07 (s, 1H, triazole-H), 
8.53 (s, 1H, -CH=N), 10.21 (s, 1H, -NH), 12.53  
(s, 1H, -NH); LC-MS [M+H]+: 470.1191. 
N-(Pyridin-4-yl)-1-(2-(((1-(2,6-difluorobenzyl)-1H- 
1,2,3-triazol-4-yl)methylene)hydrazin-1-yl)thiazole-4-
carboxamide, 8e: Yield 80%. m.p.165-167°C. 
1H NMR (500 MHz, DMSO-d6): δ 5.84 (s, 2H, -CH2), 
7.08-7.13 (m, 2H, Ar-H), 7.39 (s, 1H, thiazole-H), 
7.45-7.49 (m, 1H, Ar-H), 7.90 (d, 2H, J = 8.4 Hz,  
Ar-H), 8.07 (s, 1H, triazole-H), 8.46 (d, 2H,  
J = 8.4 Hz), 8.53 (s, 1H, -CH=N), 10.21 (s, 1H, -NH), 
12.53 (s, 1H, -NH); LC-MS [M+H]+: 441.1047. 
 
Conclusion 
In conclusion, 1-((1-(2,6-difluorobenzyl)-1H-1, 
2,3-triazol-4-yl)methylene)-2-(4-arylthiazol-2-yl) 
hydrazine derivatives 5a-h and amide derivatives of 
2-(((1-(2,6-difluorobenzyl)-1H-1,2,3-triazol-4-yl) 
methylene)hydrazin-1-yl)thiazole-4-carboxylic acid 
7a-e and 8a-e were synthesized successfully. The 
antimicrobial evaluation of the synthesized 
compounds revealed that most of the compounds were 
active against the tested microorganisms. 
Assessment of the antimicrobial activity of target 
compounds 5a-h, 7a-e and 8a-e revealed that 
introduction of thiazole ring did not show any 
noticeable effect on the activity of thiosemicarbazide 
4. The results also showed that presence of amide 
linkage on thiazole ring was more effective as 
compared to the simple aryl substitution. 
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